- NanaBis is completely built on the NanoCelle delivery...

- NanaBis is completely built on the NanoCelle delivery platform, which is the key differentiator over every other cannabinoid product or company seeking regulatory approvals globally.

- Validating NanoCelle through an FDA approved drug (NanaBis) literally *is* their core business and a major way they will generate huge concrete revenues through immediate sales and lock down big pharma partnerships on NanoCelle.

- Based on precedents such as GW Pharma's Epidiolex, or even Sativex (which I suspect was the drug NanaBis has already blown out of the water in independent testing) an FDA approval will be immensely profitable (~US$500m+ YR1 sales).

If anything, by divesting the VMS business, cutting costs and locking down funds through a Nasdaq listing, Medlab seem to be extremely focussed on their core business objectives.